NCT05982522View on ClinicalTrials.gov

IN10018 Combination Therapy in Previously-treated Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Solid Tumor
Interventions
DRUG

IN10018

orally taken once daily

DRUG

Nab-paclitaxel

125 mg/m2 D1, 8 Q3W, Intravenously

DRUG

Tislelizumab

200mg Q3W, Intravenously

All Listed Sponsors
lead

InxMed (Shanghai) Co., Ltd.

INDUSTRY

NCT05982522 - IN10018 Combination Therapy in Previously-treated Solid Tumors | Biotech Hunter | Biotech Hunter